Vera Therapeutics (NASDAQ:VERA) Issues Quarterly Earnings Results

Vera Therapeutics (NASDAQ:VERA - Get Free Report) issued its earnings results on Thursday. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.03), Briefing.com reports.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded down $1.01 during midday trading on Friday, reaching $41.32. The stock had a trading volume of 947,027 shares, compared to its average volume of 1,300,255. The stock has a market capitalization of $2.25 billion, a P/E ratio of -18.04 and a beta of 1.11. The company has a debt-to-equity ratio of 0.49, a current ratio of 7.71 and a quick ratio of 7.71. Vera Therapeutics has a 1-year low of $7.10 and a 1-year high of $50.78. The firm's fifty day simple moving average is $42.49 and its 200-day simple moving average is $28.88.

Analyst Ratings Changes

Several equities research analysts recently commented on VERA shares. Raymond James boosted their price target on Vera Therapeutics from $57.00 to $68.00 and gave the company a "strong-buy" rating in a research note on Friday. Wedbush increased their price target on shares of Vera Therapeutics from $21.00 to $34.00 and gave the stock a "neutral" rating in a research note on Thursday, March 21st. Guggenheim reaffirmed a "buy" rating and issued a $56.00 price objective on shares of Vera Therapeutics in a research note on Friday, April 5th. Finally, Oppenheimer assumed coverage on shares of Vera Therapeutics in a report on Thursday, January 25th. They issued an "outperform" rating and a $26.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vera Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $36.71.

Insider Buying and Selling at Vera Therapeutics

In other news, CFO Sean Grant sold 99,828 shares of Vera Therapeutics stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $39.61, for a total value of $3,954,187.08. Following the transaction, the chief financial officer now directly owns 66,337 shares in the company, valued at $2,627,608.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Vera Therapeutics news, SVP Joseph R. Young sold 5,714 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the sale, the senior vice president now directly owns 53,171 shares of the company's stock, valued at approximately $2,126,840. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Sean Grant sold 99,828 shares of the business's stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the transaction, the chief financial officer now owns 66,337 shares in the company, valued at approximately $2,627,608.57. The disclosure for this sale can be found here. Insiders sold 526,551 shares of company stock worth $21,533,345 over the last ninety days. Company insiders own 21.70% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.